Natural history of multiple myeloma with de novo del(17p)

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

(2017) Sharmilan Thanendrarajan et al.   HAEMATOLOGICA

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients

(2017) V Shah et al.   LEUKEMIA

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival

(2017) M Chin et al.   Blood Cancer Journal

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

(2017) Sharmilan Thanendrarajan et al.   HAEMATOLOGICA

Multiple myeloma

(2017) Shaji K. Kumar et al.   Nature Reviews Disease Primers

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

(2017) Nikhil C. Munshi et al.   JAMA Oncology

Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma

(2016) Maximilian Merz et al.   AMERICAN JOURNAL OF HEMATOLOGY

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma

(2016) M Binder et al.   Blood Cancer Journal

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

(2015) B. Hebraud et al.   BLOOD

The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma

(2015) G. An et al.   CLINICAL CANCER RESEARCH

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

(2015) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

(2015) Brian A. Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations

(2014) C. Pawlyn et al.   BLOOD

Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in -17p high risk disease

(2014) Klaus M. Kortüm et al.   BRITISH JOURNAL OF HAEMATOLOGY

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

p53 haploinsufficiency and functional abnormalities in multiple myeloma

(2014) P J Teoh et al.   LEUKEMIA

Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load

(2013) Kai Neben et al.   JOURNAL OF CLINICAL ONCOLOGY

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

(2013) S V Rajkumar et al.   LEUKEMIA

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

(2013) Joseph R. Mikhael et al.   MAYO CLINIC PROCEEDINGS

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

(2012) S. Kumar et al.   BLOOD

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

(2012) A. J. Jakubowiak et al.   BLOOD

Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

(2012) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

(2011) K. Neben et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy

(2011) Kevin D. Boyd et al.   GENES CHROMOSOMES & CANCER

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

(2011) K D Boyd et al.   LEUKEMIA

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

(2010) L. Lode et al.   HAEMATOLOGICA

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

(2010) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma

(2008) W. Xiong et al.   BLOOD

Genetic aberrations and survival in plasma cell leukemia

(2008) R E Tiedemann et al.   LEUKEMIA